Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “PROPIONATES”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 1,603 records · Page 89Linked to original sources
PubMed1977

Effect of testosterone propionate on ABP levels in rats hypophysectomised at different ages using individual sampling.

The effect of age at hypophysectomy on the response of the regressed rat testis to testosterone propionate (TP) and FSH with respect to androgen-binding protein (ABP) levels was studied in individual animals. All treatments were begun 30 days after surgery. Treatment of rats 35, 45, 55 and 75 days of age at surgery with TP (1 mg/260 g for 25 days) significantly increased the level of ABP in the testes of animals in all age groups except those hypophysectomized at 35 days of age. TP treatment did not significantly elevate epididymal levels of ABP above those found in untreated rats in any age group. In animals hypophysectomized at 100 days of age, acute treatment (3 days) with FSH (150 and 300 mug/day) significantly increases the ABP levels per testis and per epididymis. Similar treatment with 750 mug TP/day did not result in a statistically significant increase in testicular ABP. No synergism between the two hormones was noted under the conditions described. Significant restoration of testicular ABP levels per mg protein was achieved with 1 mg TP/day by 5 days of treatment. Treatment of hypophysectomized adult rats with FSH raised the epididymal/testicular ratio of ABP to about 40% of that found in intact rats while comparable treatment with TP (750 mug/day for 3 days or 1 mg/day for 10 days) only slightly affected the ratio. It is postulated that FSH may facilitate ABP transport to the epididymis in addition to affecting its production by the testis.

Aging↗
PubMed1985

Identification and occurrence of two new N-nitrosamino acids in tobacco products: 3-(N-nitroso-N-methylamino)propionic acid and 4-(N-nitroso-N-methylamino)butyric acid.

Two new N-nitrosamino acids, 3-(N-nitroso-N-methylamino)propionic acid (CAS: 10478-42-9) and 4-(N-nitroso-N-methylamino)butyric acid (CAS: 61445-55-4) were isolated and identified for the first time in various types of tobacco, including snuff, chewing and pipe tobacco, cigars and cigarettes. Their levels ranged from 0.15 to 7.4 and 0 to 2.2 mg/kg of dry weight tobacco, respectively. For comparison, amounts of other N-nitrosamino acids like N-nitrosoproline (NPRO) and tobacco-specific-nitrosamines (TSNA) were determined in the same samples. The levels of N-nitrosamino acids were highly correlated with the levels of TSNA.

Chromatography, Gas↗
PubMed1994

Duration dependent induction of invasive prostatic carcinomas with pharmacological dose of testosterone propionate in rats pretreated with 3,2'-dimethyl-4-aminobiphenyl and development of androgen-independent carcinomas after castration.

Male F344 rats were first treated with 3,2'-dimethyl-4-aminobiphenyl for 20 weeks in the presence of testicular androgens and then administered of a pharmacological dose of testosterone propionate (TP) for various periods (maximum 40 weeks). This resulted in development of invasive carcinomas in the dorso-lateral prostate as well as the seminal vesicles whose incidences were TP duration-dependent. However, in situ carcinomas of the ventral prostate were not affected by the TP treatment and atypical hyperplasias were clearly decreased. When animals were subjected to orchiectomy after 20-weeks-treatment with the TP, invasive adenocarcinomas were still subsequently noted in the dorso-lateral prostate and seminal vesicles, demonstrating a certain androgen-independence. The data indicate that, in spite of the necessity of high dose of TP for induction of invasive prostate carcinomas in the present experimental model, a proportion of the resulting tumors are hormone-independent.

Aminobiphenyl Compounds↗
PubMed1985

The excitation of frog motoneurones in vitro by the glutamate analogue, DI-alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA), and the effect of amino acid antagonists.

Intracellular recordings were made from motoneurones of the frog spinal cord in vitro and the excitatory effects of the glutamate analogue DL-alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA) examined. AMPA (25-100 microM) depolarized motoneurones with an increase in input conductance and an increase in spontaneous cell firing. The time-course of the AMPA response was prolonged compared to L-glutamate. D-Aminophosphonovalerate (1 microM) and D-aminoadipate (100 microM) did not antagonize AMPA-induced excitations while depressing L-glutamate responses. Glutamate diethylester up to 1 mM was not found to be a useful amino acid antagonist since it did not significantly reduce the depolarizations to quisqualate, L-glutamate and AMPA. The results are compatible with an action of AMPA on receptors distinct from those to N-methyl-D-aspartate and shared by quisqualate.

2-Amino-5-phosphonovalerate↗
PubMed1990

Modulation of DL-alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate (AMPA)/quisqualate receptors by phospholipase A2 treatment.

The expression of long-term potentiation (LTP) in area CA1 of hippocampus has been proposed to result from an increased sensitivity of the AMPA/quisqualate receptors. We have investigated the binding properties of excitatory amino acid receptors in phospholipase A2 (PLA2)-treated rat brain membranes. PLA2 from bee venom produced a significant increase in the binding of [3H]-AMPA ([3H]-amino-3-hydroxy-5-methylisoxazole-4- propionate), a ligand for the AMPA/quisqualate receptor. Analysis of the saturation kinetics revealed that PLA2 treatment increased the affinity of the AMPA/quisqualate receptor without changing the maximum number of sites. In contrast, PLA2 treatment did not detectably modify the binding of [3H]-kainate to the kainate receptor and of [3H]-glutamate and [3H]-glycine to the NMDA (N-methyl-D-aspartate) receptor complex. These finding suggest that phospholipase A2 may regulate the AMPA/quisqualate receptor and could play an important role in the development of LTP.

Animals↗
PubMed1994

Excitotoxins L-beta-oxalyl-amino-alanine (L-BOAA) and 3,4,6-trihydroxyphenylalanine (6-OH-DOPA) inhibit [3H] alpha-amino-3- hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA) binding in human hippocampus.

Excitotoxins L-beta-oxalyl-amino-alanine (L-BOAA) and 3,4,6-trihydroxyphenylalanine (6-OH-DOPA) have been investigated with regard to their potency to inhibit [3H] alpha-amino-3-hydroxy-5-methyl-4- isoxazole-propionic acid (AMPA) binding in human hippocampus in a quantitative autoradiographic study. With dissociation constants (KD) of [3H]AMPA binding and inhibition concentrations (IC50) of L-BOAA, 6-OH-DOPA and L-glutamate obtained from saturation and displacement experiments inhibition constants (Ki) for the inhibition of [3H]AMPA binding in individual hippocampal subregions could be calculated. They were between 5.2 +/- 2.9 and 35.1 +/- 39.9 microM for L-BOAA and 39.1 +/- 26.8 and 59.4 +/- 44.1 microM for 6-OH-DOPA. L-BOAA was equally potent as the endogenous agonist L-glutamate with Ki's between 13.1 +/- 3.9 and 21.4 +/- 12.1 microM (n = 4, mean +/- S.D.). Limbic system symptoms like cognitive deficits, mood disturbances and vivid dreams observed in patients with the motor neuron disease neurolathyrism may thus well be mediated by agonistic action of L-BOAA at AMPA glutamate receptors in hippocampus.

Aged↗
PubMed1994

Protein-synthesis inhibitor blocks (R,S)-alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA)-or substance P-induced phase shift of the circadian rhythm of neuronal activity in the rat suprachiasmatic nucleus in vitro.

The mammalian suprachiasmatic nucleus (SCN) has been identified as a circadian pacemaker. N-methyl-D-aspartate (NMDA), non-NMDA and substance P receptors have been suggested to be involved in handling of photic information in the SCN. In the Aplysia eyes, in which the circadian clocks are involved, serotonin- or cAMP-induced phase changes of the circadian rhythm were reported to be blocked by protein-synthesis inhibitors. Therefore, we investigated whether protein-synthesis inhibitor can block the non- NMDA receptor agonist (R,S)-alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid hydrobromide (AMPA)- or substance P (SP)-induced phase changes of SCN activity rhythm. Although application of 10 microM cycloheximide alone during the early part of the subjective night did not cause phase change, it blocked both 10 microM AMPA- and 1 microM SP-induced phase delay. The present result suggests that protein synthesis may be required in the manifestation of AMPA- and SP-induced phase change of circadian clock.

Animals↗
PubMed1995

Neurite outgrowth of murine cerebellar granule cells can be enhanced by aniracetam with or without alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA).

To assess the neurotrophic effects of a nootropic drug, aniracetam, we studied neurite extension of mouse cerebellar granule cells in culture with low or with high K+ under different combinations of drugs and then immunohistochemically stained the cells with an antibody against L1, a neural cell adhesion molecule on cerebellar granule cells. Quantitative analyses using parameters of the total neurite length, maximal neurite length and number of branches disclosed that aniracetam, in the presence of high K+ and alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA), significantly enhanced neurite extension of cultured granule neurons. Aniracetam alone also stimulated neurite extension of cerebellar granule cells at a longer period of culture with low K+ showing a bell-shaped dose response curve with maximal effects at 10 microM. Aniracetam may influence remodeling of the neural network after injury.

Animals↗
PubMed1996

Studies of synaptic transmission in vivo: indirect versus direct effects of (RS)-alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid/kainate antagonists on rat spinal sensory responses.

The (RS)-alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA)/kainate receptor antagonists 2,3-dihydroxy-6-nitro-7-sulfamoylbenzo[f]quinoxaline (NBQX) and 6-cyano-7-nitro-quinoxaline-2,3-dione (CNQX) were examined by microiontophoretic administration in electrophysiological tests on spinal neurones in alpha-chloralose anaesthetized rats. The antagonists significantly reduced extracellularly recorded nociceptive and non-nociceptive responses, as expected; concurrently they reduced background discharge. When the background discharge rate was held constant, the antagonists no longer significantly reduced the evoked responses. This indicates that in the absence of such control, the antagonists decreased cell excitability and only indirectly affected the test responses. Unless such indirect effects have been controlled for, the interpretation of the actions of AMPA/kainate antagonists on evoked synaptic responses is compromised and may be erroneous.

6-Cyano-7-nitroquinoxaline-2,3-dione↗
PubMed1979

Metabolism of 2-amino-3-phosphono[3-14C]propionic acid in cell-free preparations of rat liver.

Incubation of 2-amino-3-phosphono[3-14C]propionic acid with cell-free preparations of rat liver yielded labelled 3-phosphonopyruvic acid, 2-phosphonoacetaldehyde, 2-aminoethylphosphonic acid and acetaldehyde. No radioactivity was found in phosphoenolpyruvate, pyruvic acid, alanine, and phosphonoacetic acid. When added to the cell-free preparations, 3-phosphonopyruvic acid trapped the radioactivity, resulting in decrease of incorporation of the radioactivity into 2-phosphonoacetaldehyde, 2-aminoethylphosphonic acid and acetaldehyde. Incorporation of the radioactivity into 2-aminoethylphosphonic acid and acetaldehyde was also decreased by 2-phosphonoacetaldehyde. Thus it appears that the main metabolic pathway of 2-amino-3-phosphonopropionic acid is deamination to produce 3-phosphonopyruvic acid which is, in turn, converted to 2-phosphonoacetaldehyde by decarboxylation, followed by both dephosphonylation and amination of the aldehyde to give acetaldehyde and 2-aminoethylphosphonic acid, respectively.

Alanine↗
PubMed1995

Insulinotropic action of (2S)-2-benzyl-3-(cis-hexahydro-2-isoindolinylcarbonyl) propionate. I. Secretory and cationic aspects.

1. Sodium (2S)-2-benzyl-3-(cis-hexahydro-2-isoindolinylcarbonyl) propionate (KAD-1229) is a newly introduced non-sulphonylurea insulinotropic agent. 2. It failed to affect insulin release by rat islets incubated in the absence of D-glucose, slightly increased insulin output at 2.8 mM D-glucose and markedly enhanced secretion at 6.0 and 11.1 mM D-glucose. At the latter hexose concentration, the threshold concentration for the insulinotropic action of KAD-1229 was below 0.1 microM and a close-to-maximal response recorded with 1.0 microM KAD-1229. Even at 16.7 mM D-glucose, KAD-1229 (10 microM) still augmented insulin output. 3. At 6.0 mM D-glucose, KAD-1229 (0.1-1.0 microM) caused a concentration-related increase in 45Ca uptake. This coincided, in prelabelled islets, with a rapid and dual change in 86Rb outflow and dramatic increase in 45Ca outflow. 4. KAD-1229 also increased insulin release evoked by 2-ketoisocaproate (10 mM), albeit to a lesser extent than observed at a D-glucose concentration of comparable insulinotropic efficiency. 14C-labelled KAD-1229 was poorly oxidized by the islets. 5. These findings support the view that the mode of action of KAD-1229 displays analogy with that of hypoglycemic sulphonylurea.

Animals↗
PubMed1995

Insulinotropic action of (2S)-2-benzyl-3-(cis-hexahydro-2-isoindolinylcarbonyl) propionate. II. Ionophoretic and conformational aspects.

1. The non-sulphonylurea insulinotropic agent sodium (2S)-2-benzyl-3-(cis-hexahydro-2-isoindolinylcarbonyl) propionate (KAD-1229) was found to display calcium ionophoretic activity in an artificial membrane model. 2. Conformation analysis indicated that a complex between calcium and KAD-1229, with a 1:2 stoichiometry, indeed displays favourable attributes for ionophoretic activity across a hydrophobic environment. 3. It is speculated that the ionophoretic property of KAD-1229 might participate to the remodelling of cationic fluxes evoked by this insulinotropic agent in pancreatic islet cells.

Animals↗
PubMed1991

Alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid electrophysiological and neurotoxic effects in the guinea-pig cochlea.

We have recorded cochlear potentials after perilymphatic perfusion of cumulative doses of the excitatory amino acid alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) which selectively recognizes the non-N-methyl-D-aspartate ionotropic receptor formerly known as the quisqualate receptor. Our results show that AMPA (1-80 microM) caused a significant suppression of the amplitude of the compound action potential evoked by acoustic stimulation. A total elimination of this potential at the 100 microM concentration was observed in all animals. In no case was the cochlear microphonic potential, a hair cell receptor potential, affected by AMPA. Histological examinations were performed either at the end of the physiological studies or on cochleas perfused for 10 min with a single dose of AMPA (50 or 100 microM). In both experimental conditions, a selective dendritic swelling or radial afferent nerve endings under the sensory inner hair cells was observed. No damage was found in both types of hair cells supporting cells, lateral and medial efferent fibers and spiral afferent nerve ending on the outer hair cells. The occurrence of the radial dendrite swelling was prevented when 6,7-dinitroquinoxaline-2,3-dione (500 microM) was perfused in the cochlea 10 min prior, then concomitantly with AMPA. The present study strongly suggests that non-N-methyl-D-aspartate receptors, possibly of the AMPA subtype, are involved in the synaptic transmission between the inner hair cells and the primary auditory neurons. They provide further support for the hypothesis that L-glutamate, or another excitatory amino acid, acts as an inner hair cell neurotransmitter.

Acoustic Stimulation↗
PubMed1995

Developmental changes in alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate receptor properties and expression in the rat hippocampal formation.

The developmental changes in alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA) receptor properties in rat hippocampus were evaluated with quantitative autoradiography of ligand binding and in situ hybridization performed in adjacent sections with antisense oligonucleotides for AMPA receptor subunits (GluR1-3, flip and flop splice variants). Specific 3H-AMPA binding in different hippocampal subfields increased between postnatal day 7 and 15 and was higher in CA3 during the postnatal period when compared to adult levels. This effect was mostly due to high levels of high affinity binding sites in cell body layers during the developmental period. By contrast, autoradiograms of 3H-AMPA binding predominantly to the low affinity binding sites indicated an absence of these sites in cell body layers and the overall levels of binding exhibited little overshoot compared to adult levels during the developmental period. The changes in binding of the antagonist of the AMPA receptor, 6-nitro-7-cyanoquinoxaline-2,3-dione were markedly different from those for the high affinity AMPA binding sites but quite similar to those for the low affinity sites. The binding was extremely low at postnatal day 7 and increased rapidly between postnatal day 7 and 15 and slowly between postnatal day 15 and adult. Low levels of binding were observed in the cell body layer at every postnatal age. The changes in expression of messenger RNAs for the different subunits of the AMPA receptors were well correlated with the modifications in high affinity AMPA binding sites measured in the cell body layers also exhibiting an increased expression of the receptors at the transcriptional level during the developmental period as compared to adult levels. The relative expression of the GluR2 subunits decreased during the postnatal period and the time course for this reduction paralleled that for the increased vulnerability of hippocampal pyramidal neurons to a variety of insults. The results indicate that both the messenger RNAs for the subunits and the AMPA receptors exhibit increased levels of expression during the postnatal period compared to adult levels. They also suggest that nascent receptors might bind AMPA with high affinity before their insertion in membranes into functional receptors that have low affinity for agonists and high affinity for antagonists. The changes in subunit composition of the receptors during the postnatal period may have important implications for mechanisms of plasticity as well as of neuropathology.

6-Cyano-7-nitroquinoxaline-2,3-dione↗
PubMed1996

Differential effects of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid and N-methyl-D-aspartate receptor antagonists applied to the basal forebrain on cortical acetylcholine release and electroencephalogram desynchronization.

It is known that glutamatergic tracts activated from the pedunculopontine tegmentum represent a major input to the nucleus basalis magnocellularis. To establish the role of different ionotropic glutamate receptors in synaptic transmission in the basal forebrain, the pedunculopontine tegmentum was stimulated in urethane-anesthetized rats and the resulting increases in cortical acetylcholine release and desynchronization of the electroencephalogram were monitored. R(-)-3-(2-carboxypiperazine-4-yl)-propyl-I-phosphonic acid (CPP), an antagonist at N-methyl-D-aspartate-type glutamate receptors, and 6, 7-dinitroquinoxaline-2, 3-dione (DNQX), an antagonist at alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA)-type glutamate receptors, were delivered through a microdialysis probe placed in the basal forebrain. The N-methyl-D-aspartate antagonist preferentially inhibited cortical acetylcholine release, while the AMPA antagonist was more powerful in reducing desynchronization. A combination of both N-methyl-D-aspartate and AMPA antagonists abolished the increase in cortical acetylcholine release without reducing desynchronization. The dissociation between increased cortical acetylcholine release and electroencephalogram desynchronization suggests that the activity of corticopetal basal forebrain cholinergic neurons is neither necessary nor sufficient to produce electroencephalogram desynchronization. Rather, the nucleus basalis can probably affect the electroencephalogram by its projections to the thalamus. The reversal of the inhibitory effect of DNQX on the electroencephalogram by CPP may be due to the blockade of N-methyl-D-aspartate receptors on the GABAergic projection from the basal forebrain to the thalamus.

Acetylcholine↗
PubMed1981

Promoting effect of testosterone propionate on experimental exocrine pancreatic tumors by 4-hydroxyaminoquinoline 1-oxide in rats.

A single intravenous injection of 4-hydroxyaminoquinoline 1-oxide in a dose of 9 mg/kg induced exocrine adenomas of the pancreas in a significantly higher rate in male than in female rats. Castration following HAQO administration diminished the incidence of the pancreatic tumors in male rats. A combined treatment with castration and weekly injections of testosterone propionate in a dose of 1 mg/rat after HAQO administration resulted in high incidence of the pancreatic tumors in both sexes. From these findings, it is concluded that testosterone can promote the induction of the pancreatic tumors in rats by HAQO.

4-Hydroxyaminoquinoline-1-oxide↗
PubMed1987

High-performance liquid chromatographic assay of a new non-steroidal anti-inflammatory agent, 2-(10,11-dihydro-10-oxodibenzo[b,f]thiepin-2-yl)propionic acid, in human plasma and urine.

A high-performance liquid chromatographic method for the quantitation of a new anti-inflammatory agent, 2-(10,11-dihydro-10-oxodibenzo[b,f]thiepin-2-yl)propionic acid (CN-100; I), has been developed. The assay consists in extracting samples containing I and mefenamic acid, the internal standard, under acidic conditions and analysis by reversed-phase chromatography using ultraviolet detection at 330 nm. Preliminary plasma concentration-time and cumulative urinary excretion profiles from a healthy subject following oral administration of the tablet formulation are presented. This method is simple, sensitive and reproducible and is applicable to studies of the pharmacokinetic behaviour of I in humans.

Administration, Oral↗
PubMed1993

A sensitive radioimmunoassay, incorporating solid-phase extraction, for fluticasone 17-propionate in plasma.

Antibodies were produced in rabbits immunized with fluticasone 17-propionate (FP) conjugated to bovine thyroglobulin via its 3-carboxymethoxime with isobutylchloroformate. The antibodies were used to develop a sensitive and specific radioimmunoassay (RIA) for FP in human plasma. The limit of quantitation of the RIA is 50 pg per assay tube. This translates to 50 pg ml-1 plasma when a solid-phase extraction preceded the RIA. The interassay and intraassay relative standard deviations were < 15% in the centre of the assay concentration range rising to < 25% at the lower and upper limits (50 and 250 pg ml-1). No appreciable binding was seen between the antibodies and the metabolite of FP that has been identified in man. The RIA was used to study the time course of plasma concentrations in man following inhalation of FP.

Absorption↗